Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rep. Thomas Teams Up With Insmed To Promote Follow-on Biologics

This article was originally published in The Pink Sheet Daily

Executive Summary

Former Rep. Bill Thomas continues his crusade for follow-ons and against Amgen in his new role as consultant to Richmond, Va.-based Insmed, which has big plans for follow-on biologics.

You may also be interested in...



Bill Thomas' Battle Plan For Cutting Biologics' 12-Year Exclusivity

The former chairman of the House Ways and Means Committee explains how Senate floor debate is key to forcing revisions in the FOB provisions of the health care reform legislation.

Bill Thomas' Battle Plan For Cutting Biologics' 12-Year Exclusivity

The former chairman of the House Ways and Means Committee explains how Senate floor debate is key to forcing revisions in the FOB provisions of the health care reform legislation.

Amgen Pays $200M To Settle Antitrust Claim

No wrongdoing admitted in case filed by Ortho Biotech over anemia drugs.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS068105

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel